Richard Law
Stock Analyst at Goldman Sachs
(0)
# 4639
Out of 5,270 analysts
59
Total ratings
23.08%
Success rate
-17.31%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Rocket Pharmaceutica... | Maintains: Neutral | 29 15 | 8.81 | 70.26% | 2 | Mar 3, 2025 | |
Celldex Therapeutics | Maintains: Neutral | 42 36 | 19.38 | 85.76% | 2 | Mar 3, 2025 | |
MoonLake | Maintains: Buy | 82 73 | 39.7 | 83.88% | 3 | Feb 27, 2025 | |
Mineralys Therapeuti... | Maintains: Buy | 28 24 | 8.98 | 167.26% | 6 | Feb 13, 2025 | |
Viridian Therapeutic... | Maintains: Strong Buy | 25 31 | 14.4 | 115.28% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 24 | 4.21 | 470.07% | 4 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 11 | 5.5 | 100% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 31 | 6.18 | 401.62% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 46 47 | 25.08 | 87.4% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 62 63 | 42.26 | 49.08% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 37 | 30.14 | 22.76% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 76 | 9.45 | 704.23% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 36 | n/a | n/a | 4 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 14 | 1.77 | 690.96% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 61 | 16.27 | 274.92% | 4 | May 8, 2023 |